Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Jun 4, 2023. (Total: 217641Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 10 (of 10 Records)

Query Trace: Hypercholesterolemia and CYP3A5[original query]
CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
Clinica chimica acta; international journal of clinical chemistry 2008 Dec 398 (1-2): 15-20.
Willrich Maria Alice V, Hirata Mario H, Genvigir Fabiana D V, Arazi Simone S, Rebecchi Ivanise M M, Rodrigues Alice C, Bernik Marcia M S, Dorea Egidio L, Bertolami Marcelo C, Faludi André A, Hirata Rosario D
Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Clinica chimica acta; international journal of clinical chemistry 2011 Nov .
Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA
CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
Journal of clinical pharmacy and therapeutics 2012 Dec 37 (6): 719-23.
Jiang X-Y, Zhang Q, Chen P, Li S-Y, Zhang N-N, Chen X-D, Wang G-C, Wang H-B, Zhuang M-Q, Lu
Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.
Pharmacogenomics 2013 Jan 14 (1): 1.
Hu M, Mak VW, Xiao Y, Tomlinson B
Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
Clinica chimica acta; international journal of clinical chemistry 2013 Mar .
Willrich MA, Rodrigues AC, Cerda A, Genvigir FD, Arazi SS, Dorea EL, Bernik MM, Bertolami MC, Faludi A, Largura A, Baudhuin LM, Bryant SC, Hirata MH, Hirata RD
Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin.
The open cardiovascular medicine journal 2014 8 12-7.
Kolovou Genovefa, Ragia Georgia, Kolovou Vana, Mihas Constantinos, Katsiki Niki, Vasiliadis Ioannis, Mavrogeni Sophie, Vartela Vassiliki, Tavridou Anna, Manolopoulos Vangelis
POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.
Pharmacogenomics 2014 Dec 15 (16): 1963-72.
Drogari Euridiki, Ragia Georgia, Mollaki Vasiliki, Elens Laure, Van Schaik Ron H N, Manolopoulos Vangelis
A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents.
European journal of clinical pharmacology 2019 Jun .
Ogungbenro Kayode, Wagner Jonathan B, Abdel-Rahman Susan, Leeder J Steven, Galetin Aleksand
SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability.
Journal of personalized medicine 2021 Mar 11 (3): .
Zubiaur Pablo, Benedicto Maria Dolores, Villapalos-García Gonzalo, Navares-Gómez Marcos, Mejía-Abril Gina, Román Manuel, Martín-Vílchez Samuel, Ochoa Dolores, Abad-Santos Francis
Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.
PloS one 2022 17 (7): e0260824.
Elalem Elbatool G, Jelani Musharraf, Khedr Alaa, Ahmad Aftab, Alaama Tareef Y, Alaama Mohamed Nabeel, Al-Kreathy Huda M, Damanhouri Zoheir
TOP